Dr. Reddy's in Clinical Trials for Cardio Compound in Ireland

Indian drugmaker Dr. Reddy's has begun Phase I clinical trials for a new compound, known as RUS 3108, to treat atherosclerosis, a significant cause of cardiovascular events such as heart attack and stroke. The company claims that the prospective drug, currently under study at its facility in Ireland, induces a protein called perlecan. This substance purportedly alleviates conditions associated with the artery-hardening condition.

Dr. Reddy's, like many Indian drugmakers, has expanded heavily in R&D in recent years as it diversifies away from its origins in the generics sector. The company now claims to have six new chemical entities under development.